Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.77 USD
-0.07 (-3.80%)
Updated May 17, 2024 04:00 PM ET
After-Market: $1.77 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LXRX 1.77 -0.07(-3.80%)
Will LXRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LXRX
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates
All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy
LXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates
Other News for LXRX
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
Lexicon announces new post-hoc analysis of data on INPEFA
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript
Analysts Are Bullish on These Healthcare Stocks: Cigna (CI), Lexicon Pharmaceuticals (LXRX)